Ovarian cancer screening: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) No edit summary |
Hudakarman (talk | contribs) No edit summary |
||
| Line 16: | Line 16: | ||
**[[Transvaginal ultrasound]] ([[TVU]]) | **[[Transvaginal ultrasound]] ([[TVU]]) | ||
**Multimarker panels and bioinformatic analysis of proteomic patterns<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086 }} </ref> | **Multimarker panels and bioinformatic analysis of proteomic patterns<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086 }} </ref> | ||
*The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)is evaluating a multimodal screening strategy (MMS) efficacy which consists of: | *The [[UK Collaborative Trial of Ovarian Cancer Screening]] ([[UKCTOCS]])is evaluating a multimodal [[screening]] [[strategy]] ([[MMS]]) [[efficacy]] which consists of: | ||
** | **Annual [[CA125]] screening, risk of [[ovarian cancer]] algorithm ([[ROCA]]), TVU <ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086 }} </ref> | ||
*Patients with family history of ovarian cancer or breast cancer can have ovarian cancer hereditary syndrome as breast-ovarian cancer syndrome which is associated with | *Patients with family history of [[ovarian cancer]] or [[breast cancer]] can have [[ovarian cancer hereditary syndrome]] as [[breast-ovarian cancer syndrome]] which is associated with | ||
**BRCA1 and BRCA2 gene mutations | **[[BRCA1]] and [[BRCA2]] [[gene mutations]] | ||
**Lynch II syndrome | **[[Lynch II syndrome]] | ||
*Should undergo the following screening: | *Should undergo the following [[screening]]: | ||
**Annual rectovaginal pelvic examinations | **[[Annual]] [[rectovaginal]] [[pelvic examinations]] | ||
**CA 125 | **[[CA 125]] | ||
**TVU | **[[TVU]] until completing [[childbearing]] or until age 35 years at least, where at this point [[prophylactic]] [[bilateral]] [[oophorectomy]] is recommended<ref name="pmid28170086">{{cite journal| author=Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al.| title=Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. | journal=CA Cancer J Clin | year= 2017 | volume= 67 | issue= 2 | pages= 100-121 | pmid=28170086 | doi=10.3322/caac.21392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28170086 }} </ref> | ||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 18:39, 12 July 2019
|
Ovarian cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian cancer screening On the Web |
|
American Roentgen Ray Society Images of Ovarian cancer screening |
|
Risk calculators and risk factors for Ovarian cancer screening |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
- There are no recommendations for screening ovarian cancer in asymptomatic women although better outcome is associated with early diagnosis[1]
- Ovarian cancer is the fifth most common cause of cancer-related mortality in women
- 75% of women with ovarian cancer are diagnosed in an advanced stage
- Ovarian cancer is the most lethal gynecological cancer[2]
- The reason of increased mortality and late detection of ovarian cancer in its advanced stage is because the screening systems that are being used have poor or limited sensitivity and specificity[1].
- Biomarkers from peritoneal fluid can be used as a mean of ealy detection of ovarian cancer but this is stil an emerging proof.
- Examples of screening and diagnostic methods for ovarian cancer include:
- Pelvic examination
- Cancer antigen 125 (CA 125) tumor marker
- Transvaginal ultrasound (TVU)
- Multimarker panels and bioinformatic analysis of proteomic patterns[2]
- The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)is evaluating a multimodal screening strategy (MMS) efficacy which consists of:
- Annual CA125 screening, risk of ovarian cancer algorithm (ROCA), TVU [2]
- Patients with family history of ovarian cancer or breast cancer can have ovarian cancer hereditary syndrome as breast-ovarian cancer syndrome which is associated with
- Should undergo the following screening:
- Annual rectovaginal pelvic examinations
- CA 125
- TVU until completing childbearing or until age 35 years at least, where at this point prophylactic bilateral oophorectomy is recommended[2]
References
- ↑ 1.0 1.1 Galea M, Gauci G, Calleja-Agius J, Schembri-Wismayer P (2017). "Peritoneal biomarkers in the early detection of ovarian cancer". Minerva Ginecol. 69 (1): 84–99. doi:10.23736/S0026-4784.16.03943-5. PMID 27284942.
- ↑ 2.0 2.1 2.2 2.3 Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D; et al. (2017). "Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening". CA Cancer J Clin. 67 (2): 100–121. doi:10.3322/caac.21392. PMID 28170086.